Biofrontera

Biofrontera EBIT per Share

The EBIT per Share of Biofrontera (B8FK.DE) as of Nov 21, 2026 is -0.17 EUR. In the previous year, EBIT per Share was -0.26 EUR — a change of -35.59% (higher).

EBIT per Share

-0.17EUR

YoY

-35.59%

Last updated:

EBIT per Share of Biofrontera is 2025 -0.17 EUR. EBIT per Share of Biofrontera was 2024 -0.26 EUR. It decreases by -35.59% higher compared to the previous year.

The Biofrontera EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2019
-0.52 EUR
Jan 1, 2020
-0.13 EUR
Jan 1, 2021
-0.62 EUR
Jan 1, 2022
0.02 EUR
Jan 1, 2023
0.07 EUR
Jan 1, 2024
-0.26 EUR
Jan 1, 2025
-0.17 EUR
Jan 1, 2026 (e)
2.75 EUR
The Biofrontera EBIT per Share history
YEAREBIT per ShareYoY
est2.75EUR-1,733.33%
-0.17EUR-35.59%
-0.26EUR-448.46%
0.07EUR+200.75%
0.02EUR-104.00%
-0.62EUR+398.12%
-0.13EUR-76.00%
-0.52EUR+26.51%
-0.41EUR+32.61%
-0.31EUR+18.30%
-0.26EUR+15.13%
-0.23EUR+7.39%
-0.21EUR+33.47%
-0.16EUR-37.94%
-0.26EUR-64.17%
-0.72EUR-28.51%
-1.00EUR+12.48%
-0.89EUR-36.15%
-1.39EUR+41.65%
-0.98EUR+34.93%
-0.73EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

EBIT per Share of Biofrontera is -0.17 EUR in 2025.

EBIT per Share of Biofrontera changed from -0.26 EUR to -0.17 EUR, representing a -35.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Biofrontera since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biofrontera

All Key Metrics — Biofrontera